Vivek Ramaswamy Emerges As A Strong Contender 

Vivek Ramaswamy has emerged as something of a breakout star in the 2024 GOP presidential primary, raising speculation over his future within the party.

Many Republicans have praised the 37-year-old biotech entrepreneur, calling him an effective communicator with an impressive professional resume for a political outsider.

The biotech entrepreneur and author of “Woke, Inc.: Inside Corporate America’s Social Justice Scam” is an audience favorite at multicandidate events and has polled well despite not being nationally known when he entered the race.

“Take it from me as a young person — I’m 37 years old. I was born in 1985. I truly hope and pray and believe that my best days may still be ahead of me,” he said at the Faith and Freedom conference in Washington, D.C. in June.

Ramaswamy’s campaign says he met the donor threshold earlier this year. This summer he rolled out “Vivek’s Kitchen Cabinet” to boost his donor numbers even more, by letting fundraisers keep 10% of what they bring in for his campaign.

While there’s heavy scepticism that Ramaswamy will win any of the early-state primaries, many see him as a rising figure within the party’s ranks.

Picture : MediaLite

“I think that his message is resonating well with the Republican activist crowd, and he is being positive enough with regards to [former President] Trump to basically be an alternative without being an anti-Trump guy,” said GOP strategist and former Michigan GOP Chairman Saul Anuzis.

“I think that resonates with many of the Trump supporters and let’s say soft Trump supporters who would like to move on, but yet see somebody who’s not running kind of on a message of attacking Trump and his legacy,” he added.

Initially considered a long-shot candidate when he launched his campaign in February, the “Woke, Inc.” author entered the race known in part for his staunch opposition to environmental, social and corporate governance (ESG) policies.

But the political outsider and first millennial to run for president on the GOP side has started to catch some momentum in the GOP primary.

He’s garnered attention for some of his stances and proposals, including pushing every candidate in the GOP primary to commit to pardoning Trump over the Justice Department’s indictment alleging the former president mishandled and obstructed attempts to retrieve classified documents. Other Republican contenders like Perry Johnson have also vowed to pardon the former president.

Earlier this month, Ramaswamy gained some praise after a video went viral of him engaging with a protester who interrupted his Iowa event. After the woman turned to leave after interrupting his remarks, Ramaswamy offered for her to come back to ask a question.

“There is a division in our country and I think people are hungry to start talking openly again, and I think Vivek has a unique skill that he’s able to really lead people and rally people around what this country was founded upon, which is free speech, which is an open debate,” said Ramaswamy campaign senior adviser Tricia McLaughlin.

“I think that’s what not only the GOP electorate is hungry for, but I think independents and even disaffected Democrats,” she added.

National polling, too, suggests voters are starting to give Ramaswamy a serious look.

A RealClearPolitics polling average shows Ramaswamy placing third at 5.4 percent, behind Trump in first place with 52.4 percent and DeSantis at 18.4 percent.

Still, most national polls show the biotech entrepreneur in the single digits compared to Trump, who remains the front-runner in surveys. Some early state polls in New Hampshire and South Carolina show Ramaswamy trailing some of the other GOP candidates, such as Florida Gov. Ron DeSantis and Sen. Tim Scott (S.C.).

Republicans also acknowledge more GOP voters will start to tune into the primary around next month’s debate in Milwaukee and note there’s still months to go until the first early states’ primaries.

Not all Republicans are buying the Ramaswamy hype. GOP pollster and consultant Whit Ayres said the GOP millennial is “not a serious contender for the presidency” and waved off Ramaswamy’s recent polling.

“It’s a sign just like Herman Cain caught something in 2011 and Ben Carson caught something in 2015 and Andrew Yang caught something in 2020,” Ayres said, referring to presidential candidates who appeared to have momentum at one point in their primary before sputtering out.

New Hampshire-based strategist Matthew Bartlett similarly suggested that Ramaswamy doesn’t have a viable path to the presidency. Putting it bluntly, Bartlett said, “No one is expecting him to win,” and he said he didn’t see Ramaswamy going after the former president in the primary but was “looking to cozy up to Trump.”

“His campaign was not looking to end up in the Oval Office. His campaign was to promote himself and to some degree, his ideas and articulate that,” he added.

But that hasn’t stopped members of the party from suggesting that Ramaswamy could have a bright future ahead, saying he could run for Senate, be picked for a presidential cabinet position or even selected as someone’s running mate.

“There’s so many people even after the Family Leadership Summit [who] said, ‘Boy, what a young, positive, inspirational guy. He has a bright future. He’d be good in somebody’s cabinet. He might be a vice president,’” explained Bob Vander Plaats, president and CEO of the influential Family Leader in Iowa.

“His biggest hurdle right now is crossing that threshold where people say, ‘No, I think he can be president.’ So he’s gotten a lot of people excited about his candidacy. Now he needs to make that transition: ‘Now they can see me be president,’” he added.

Ramaswamy for his part has previously said he’s not interested in being a vice presidential pick or taking a cabinet position, saying he’d return to the private sector instead if he didn’t win the GOP presidential primary. But his campaign argues he shouldn’t be underestimated.

“I think Vivek has already done what everyone said he couldn’t do. The fact that he is beating … the most former vice president, multiple governors, the former U.N. ambassador, a sitting senator … four or five months ago, no one knew who Vivek Ramaswamy is,” McLaughlin, the senior Ramaswamy campaign adviser, said. “And now he’s third in national polls. That in itself is meteoric.”

Republican strategists, too, say that while Trump is still the front-runner in the primary, a strong showing in Iowa can help galvanize a candidate heading into the next few states.

“I wouldn’t count anyone out that’s coming in the top three in Iowa,” said GOP strategist Alice Stewart, who’s an alum of multiple presidential campaigns. “And the objective of Iowa has never been to choose the party nominee, it’s to winnow the field.”

Vivek Ramaswamy And the Christian Language of Hinduism

(RNS) — Like many Republican presidential candidates, Vivek Ramaswamy has been outspoken about the role of faith and society. An enthusiastic second-generation Indian American, Ramaswamy also isn’t shy about talking about his own faith.

“I’m a person of faith. Evangelical Christians across the state are also people of faith,” he said in a July interview with NBC News. “We found commonality in our need to defend religious liberty, to stand for faith and patriotism and stand unapologetically for the fact that we are one nation under God.”

To reach evangelical Christians, the largest religious group skewing Republican, Ramaswamy has affirmed both his Hindu identity and the Judeo-Christian civic religion in which he was raised. Ramaswamy attended Catholic School where he studied the Bible, uniquely positioning him to use both fai

Not everyone is happy with that message. Earlier this week, a conservative pastor went viral for his condemnation of Ramaswamy’s faith.

“If he does not serve the Lord Jesus Christ and stand primarily for Judeo-Christian principles, you will have a fight with God,” said Hank Kunneman, of One Voice Ministries, in a video tweeted by Right Wing Watch on July 24. “You are going to let him put all of his strange gods up in the White House and are we just supposed to blink because he understands policies? No.”

Hindu Americans across the country condemned the pastor’s remarks, including Democratic Congressmen Raja Krishnamoorthi and Ro Khanna. The United States-India Relationship Council, a political action committee dedicated to supporting political candidates who are pro-India, released a public statement.

“We need to expose and condemn this bigotry,” said Amit Desai, founder of the PAC. “By doing so, people will get educated.”

The ancient tradition of Sanatana Dharma — more commonly known as Hinduism — has long been misunderstood by unfamiliar audiences, especially in places like the United States, where Christianity predominates.

A tradition that has more than a billion adherents worldwide, Hinduism does not always fit neatly into categories understood by those more familiar with Abrahamic faiths like Christianity, Islam and Judaism. Hindus hold a pluralistic worldview in which many paths exist to experiencing the supreme, eternal spirit of reality known as Brahman.

Brahman, sometimes referred to as God, is a genderless and metaphysical concept, but Hindus believe it manifests itself in the sometimes human-like forms of gods and goddesses. Many Hindus can see the divine revealing itself in the holy people of other religious traditions.

Hindus worship at temples and within their homes to as many murtis as they wish, or embodied forms of God. Families and communities within Hinduism can also have a patron deity, known as an Ishta Devata, that they especially venerate.

To help people from other backgrounds better understand their faith, Ramaswamy, like other American Hindus, has emphasized the elements of Hinduism that relate closely to Christianity — such as a focus on one God that all of humanity shares.

The Hindu American Foundation, the largest nonprofit representing the religious community, has started shifting away from using the word “idol,” instead using “deity,” so as to eliminate the chance of misunderstanding by Christians.

Suhag Shukla, executive director of HAF, says that even though God might not necessarily be the appropriate word to equate to Brahman, saying God is the fastest way to communicate with other faith traditions.

“When your goal is to educate people who are wholly unfamiliar with a tradition or a philosophy or religion, you have to meet them where they are,” said Shukla. “The words that might have some resonance for Christians is a good starting point.”

Anantanand Rambachan, a Hindu theologian and author of “Pathways to Hindu-Christian Dialogue,” says that, while it is not incorrect to say Hindus worship one divine being, practitioners should not shy away from explaining that this one being has infinite names and forms. The faith is neither polytheistic nor monotheistic, he says, but something entirely more complex.

“In communicating our tradition, we should not be afraid to be different,” said Rambachan. “To reduce the murtis (idols) only to a symbol, is not to be faithful to centuries of a very sophisticated theology.”

Back in 2007, as the first non-Christian chair of the Religion Department at St. Olaf College, a Lutheran school in Minnesota, Rambachan faced his share of backlash from critics who insisted he could not serve a largely Christian student body.

“Communicating the Hindu point of view in all of its richness and its integrity is possible, but it takes time,” said Rambachan. “Those who are formed and steeped in an exclusive theological position — it is not easy to open their hearts and minds.”

While Hindus have overwhelmingly voted Democrat, some in the community say they are disappointed with the party for not standing against anti-Hindu hatred they say is rampant.

For Desai, a leader of USIRC, Ramaswamy’s battle against what he calls “woke-ism” and his embracing of young voters is enough to sway his vote. He points to Rishi Sunak, the prime minister of the UK and a member of the Conservative Party, as an example of someone who has held his Hindu faith on unapologetic display.

Hirsh Vardhan Singh Of New Jersey Announces Bid For US President

Filing his candidacy, Hirsh Vardhan Singh, an Aerospace engineer from New Jersey, has become the fourth Indian-American to enter the race for 2024 US Presidential Polls. On Thursday, July 27, 2023, he formally submitted his candidature to the Federal Election Commission.

He is the third Indian American to join numerous Republicans vying for their party’s endorsement to run for President. The other two are former governor of South Carolina Nikki Haley and entrepreneur Vivek Ramaswamy.

Taking to X, formerly known as Twitter, Singh posted a video and said he is a “lifelong Republican” and “America First” conservative who worked to restore a conservative wing of the New Jersey Republican Party. In the video, he criticized the “corruption” of Big Tech and pharmaceutical firms, saying they had “relentlessly attacked our freedoms.”

“We need strong leadership to reverse the changes that have occurred in the past few years and restore American values. That is why I have decided to seek the Republican Party’s nomination for the 2024 election for the office of president of the United States,” Singh said in his video, according to The Hill.

With a dozen contenders vying for the Republican nomination, including former president Trump, Singh joins a crowded field.
Singh entered the Republican primaries for New Jersey governor in 2017 and 2021, a House seat in 2018, and the Senate in 2020, but he was unable to secure the party’s nod.

Aerospace engineer Hirsh Vardhan Singh has become the third Indian-American vying for the Republican nomination for the 2024 US presidential race after former South Carolina Governor Nikki Haley and entrepreneur Vivek Ramaswamy.

Singh joins a crowded list of Republican candidates vying for presidency, which includes Trump, former New Jersey Governor Chris Christie, Florida Governer Ron DeSantis, former Vice President Mike Pence, Ramaswamy, Haley, Senator Tim Scott and businessman and pastor Ryan Binkley.

Singh, 38, introduced himself as a lifelong Republican and an “America First constitutional carry and pro-life conservative who helped restore the conservative wing of New Jersey’s Republican Party starting in 2017” in a video message posted on Twitter on Thursday.

He ran unsuccessfully for the US Senate in 2020, and the present bid is the fourth time the defense and aerospace industry executive is eyeing public office.

According to Singh, Americans face grave threats from the corruption of both, big tech and big pharma, and in addition, there is an all out attack on American family values, parental rights and open debate.

“While Big Pharma has made massive profits working with the government to compel everyone to take the experimental vaccines, Big Tech has become the Big Brother, who invades our privacy and indulges in censorship of our political and contrarian viewpoints,” her said in an over three-minute-long video.

“We need strong leadership to restore American values. That is why I have decided to seek the Republican Party’s nomination for the 2024 election,” he added.

While praising fellow Republican candidate Donald Trump as the “greatest president of my lifetime”, Singh said that “America needs more”.

“It is time to move past outdated politicians of a bygone era,” Singh said, calling himself the “only pure blood candidate for the President” as he never gave in to the Covid vaccinations. “Even New Jersey’s Democrat Senate President labelled me as ‘Trump on steroids,” he said in his video message.

According to a recent Morning Consult poll, 59 per cent of voters support Trump, 16 per cent would vote for DeSantis, 8 per cent to Ramaswamy, 6 per cent to Pence, and 2 per cent to Scott.

Born to Indian immigrant parents, Singh has a bachelor’s degree in engineering from the New Jersey Institute of Technology in 2009. Entering New Jersey politics in 2017 as a candidate for Governor, Singh finished third in the race, securing a meagre 9.8 per cent of the vote share.

He was awarded Aviation Ambassador in 2003 by the American Institute of Aeronautics and Astronautics. (IANS)

Shiva Ayyadurai Announces 2024 U.S. Presidential Bid

The 2024 United States Presidential elections is turning out to be an Indian American affair as tech entrepreneur Shiva Ayyadurai became the fourth candidate from the community to announce his bid for the country’s top post.  Scientist and entrepreneur, Shiva Ayyadurai is running as an independent candidate.

Announcing his campaign bid recently, the 59-year-old Mumbai-born said he wants to serve America, beyond “Left” and “Right” to deliver solutions people need and deserve.

“I am running for President of the United States of America. We stand at the crossroads where we can either head into a Golden Age or into the Darkness… America becomes great when innovators, entrepreneurs, working people with skills and those committed to using common sense and reason run this country,” Ayyadurai said. “We stand at crossroads where we can either head into a Golden Age or the Darkness. I stand before you as someone who is a personification of the American Dream.”

On his campaign website, Ayyadurai maintained that America becomes great when innovators, entrepreneurs, working people with skills and those committed to using common sense and reason run the country. He added, “The Founders of America were blacksmiths, engineers, soldiers, architects, entrepreneurs, scientists — they worked for a living and produced through their labor, products and services to help other citizens.”

He is now the fourth Indian-American to bid for the US presidency, following Indian-American aerospace engineer Hirsh Vardhan Singh, former South Carolina Governor Nikki Haley, and entrepreneur Vivek Ramaswamy.

A Fulbright Scholar with four degrees from the Massachusetts Institute of Technology, Ayyadurai has started seven hi-tech companies, including EchoMail, CytoSolve, and Systems Health. He is said to have “invented email” at the age of 14. Currently, he serves as the Founder and CEO of CytoSolve, Inc, which is working on discovering cures for major diseases, from pancreatic cancer to Alzheimer’s.

The 59-year-old MIT scholar, who “invented email” when he was just 14, had earlier made headlines when he expressed interest in taking up the position of Twitter’s chief executive officer after Elon Musk said he wishes to step down from the post.

Mumbai-born Ayyadurai is an award-winning scientist and recently invented CytoSolveⓇ, a revolutionary platform for modeling complex biological phenomena, to support the development multi-combination medicines without animal testing. His parents immigrated to the US in 1970, when he was seven years old and settled in Paterson, New Jersey.

The question remains, if a foreign born US citizen is able to run for President’s office!

Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion

Axovant Sciences (NASDAQ:AXON) has announced that Gavin Corcoran, MB BCh, FACP, will join the Company as Executive Vice President of Research & Development, and Michael Hayden, MB ChB, PhD, FRSC, has been appointed as a senior scientific advisor to the company and Chairman of Axovant’s newly established Scientific Advisory Board.

“I am pleased to welcome Gavin and Michael to the Axovant team,” said Pavan Cheruvu, MD, Chief Executive Officer of Axovant. “Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organization, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy. We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.”

“I am very excited to join Axovant at this turning point,” said Dr. Corcoran. “I look forward to working closely with Pavan and the senior management team to bring new investigational medicines into the portfolio as we build upon Axovant’s capabilities in research and development. We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases. I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”

“I share Pavan’s vision of rebuilding the company on a foundation of transformative science and I look forward to expanding Axovant’s Scientific Advisory Board,” said Dr. Hayden. “I have been very impressed with the caliber of the Axovant team and am excited about the future growth of the company.”

Dr. Gavin Corcoran has overseen successful drug development across multiple therapeutic areas including neurology and psychiatry. He currently serves as Chief Medical Officer at Allergan plc, and previously served as Chief Medical Officer of Actavis. Dr. Corcoran was Executive Vice President for Global Medicines Development at Forest Laboratories prior to the acquisition of Forest Laboratories by Actavis. In addition, Dr. Corcoran served as Head of Late Stage Clinical Development for Inflammation and Immunology at Celgene, and as Chief Scientific Officer and head of R&D at Stiefel Laboratories. Earlier in his career he held leadership roles in clinical development and regulatory affairs at Amgen, Schering-Plough, and Bayer. He received his MB BCh from the University of the Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.

Dr. Michael Hayden is one of the world’s leading experts in the genetic basis of movement disorders and CNS drug development. He recently served as President of Global R&D and Chief Scientific Officer at Teva. Prior to Teva, he founded multiple biotechnology companies, including Aspreva Pharmaceuticals. He currently serves as Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden played a key role in the discovery and development of GLYBERA®, the first approved gene therapy product in the Western world, and has received numerous awards including the Order of Canada, granted for his contributions to the understanding of Huntington’s disease and other genetic disorders. In 2008 he was named Canada’s Health Researcher of the Year and in 2017 he was inducted into the Canadian Medical Hall of Fame. Dr. Hayden received his MB ChB, PhD in Genetics, and DCH Diploma in Child Health from the University of Cape Town in South Africa. He completed his clinical training in internal medicine and clinical genetics at Harvard Medical School.

Beginning in February 2018, Axovant initiated an organizational restructuring to simplify its organization, reduce costs, and streamline business processes in preparation for future business development activities.

As part of the restructuring plan, Axovant enhanced its capabilities in clinical research and business development, while reducing the size of its global commercial team. Overall, internal headcount has decreased by approximately 43%, and Axovant has increased its use of the Roivant platform to supplement internal capabilities. Forward-looking G&A expenses are expected to decrease in the current fiscal year. Most of the affected employees were transferred to roles within the Roivant family of companies.

“Roivant supports Axovant’s plans for pipeline expansion and organizational transformation,” said Vivek Ramaswamy, Chief Executive Officer of Roivant. “We are committed to hiring and developing high-caliber talent, and we were pleased to support many of Axovant’s employees in finding new roles within the Vant family. I am excited about the new direction that Axovant is taking.”

Axovant is a clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for patients with serious neurologic and neuropsychiatric conditions, and turning promising therapies into lasting solutions for patients. Axovant is committed to developing and commercializing a pipeline of product candidates by identifying and developing novel treatments for unmet needs in neurology and psychiatry.

Roivant Sciences is a global biopharmaceutical company focused on reducing the time and cost of the drug development process to improve the lives of patients and their families. Roivant partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly delivered to patients.

2 Indians in Forbes list of US’ richest under-40 entrepreneurs

Two Indian Americans, investor Vivek Ramaswamy and Instacart founder Apoorva Mehta, were named among Forbes’ “Richest Entrepreneurs Under 40” list, now in its second year. Biotech entrepreneur Vivek Ramaswamy has been ranked 24th on ‘America’s Richest Entrepreneurs Under 40 2016’ list with a networth of $600 million, and Instacart co-founder Apoorva Mehta, stands at the 31st spot with a $360-million networth.

Ramaswamy, 31, a Harvard University and Yale School of Management alumnus, continues to make waves in the biotech business with his deals and drug development plans, Forbes said. He was behind the biggest biotechnology IPO of 2016, Myovant Sciences, which raised $218-million listing its shares on Nasdaq in October, it said.

Last year, Ramaswamy pulled off the biggest IPO in the US biotech history by listing shares of Axovant, a company that is trying to develop a new Alzheimer’s drug. He runs Roivant Sciences, a biotech holding company with an innovative financial strategy to develop drugs, often by purchasing drugs that have been forgotten or abandoned by the pharmaceutical industry.

He made his roughly $600 million net worth on his own accord and through investments, and continues to make waves in the biotech business with his deals and drug development plans, Forbes said. He was behind the biggest biotechnology initial public offering of 2016, Myovant Sciences, which raised $218 million listing its shares on Nasdaq in October, it added. Ramaswamy formed the company in April and struck a deal with Takeda Pharmaceuticals for a prostate cancer drug and a female infertility drug.

Forbes called Mehta one of Silicon Valley’s youngest immigrant success stories. Born in India, Mehta and his family moved to Canada in 2000, where he studied engineering at the University of Waterloo before working at Blackberry, Qualcomm, and then Amazon. In 2012, he co-founded Instacart, a grocery-delivery service that partners with grocery chains. The company is valued at an estimated $2 billion, and most recently raised funding from Whole Foods Market in March, it said.

The 30-year-old Mehta would not have been included on the list in the inaugural year of 2015. A year ago, the cutoff to make the list was $400, but that dropped drastically with a number of entrepreneurs aging out. The cutoff in 2016 came in at $270 million, allowing the Instacart founder to place No. 31 on the list with his net worth of $360 million.

Mehta is one of Silicon Valley’s youngest immigrant success stories, Forbes said. Born in India, Mehta and his family moved to Canada in 2000, where he studied engineering at the University of Waterloo before working at Blackberry, Qualcomm and then Amazon.

Vivek Ramaswamy, Apoorva Mehta among richest entrepreneurs under 40

Vivek Ramaswamy, 30, a former hedge fund manager, has been ranked 33rd on the list with a net worth of $500 million. Forbes said his source of wealth is investments. On the 40th spot is 29-year old Apoorva Mehta, the founder and CEO of web-based grocery delivery service Instacart. Mehta’s net worth is $400 million.

Zuckerberg leads the pack with a net worth of $47.1 billion, more than four times as much as the second person in the ranks, his co-founder and college friend Dustin Moskovitz. At number three is Jan Koum, who came to America at age 16. He started WhatsApp, now the world’s biggest mobile messaging service with 800 million users, in 2009 and sold it to Facebook for about $22 billion in cash and stock in 2014.

Forbes said California techies dominate the first ever list of the nation’s 40 most successful young entrepreneurs under the age of 40, “reaffirming the American Dream and proving yet again that there is no better way right now to get rich fast than to go west and convince venture investors to back your most ambitious ideas”. Elizabeth Holmes is the only woman to make the ‘America’s Richest Entrepreneurs Under 40’. Holmes quit Stanford at age 19 to start blood testing company Theranos. All of the young entrepreneurs in the list have a net worth of $400 million or more and 34 made their money in the tech sector.

Twenty-one are billionaires and many either created or work for some of the hottest tech companies, including Uber, AirBnB, Fitbit, GitHub, Instacart and Pinterest. The list’s youngest member is Palmer Luckey, who was just 21 years old when he sold his virtual reality equipment company, Oculus, to Facebook for $2.3 billion in July 2014. Luckey’s net worth is $700 million and is one of half a dozen in the ranks who are still in their 20s, Forbes said. Two Indian-origin businessmen have been ranked by Forbes magazine among the richest entrepreneurs in America under the age of 40, a list that has been topped by Facebook CEO Mark Zuckerberg.

Entrepreneur Vivek Ramaswamy Featured on Forbes Cover

Indian American entrepreneur Vivek Ramaswamy, 30, shocked a lot of people when he turned $5 million into $3 billion with Axovant Sciences’ initial public offering. Now, as featured in the Sept. 28 cover story for Forbes Magazine, Ramaswamy is poised to repeat history.
In June, Ramaswamy was at the forefront of the biggest IPO in the history of the American biotechnology industry. The Bermuda-based company, with offices also in New York, has just one product: a dementia drug to treat Alzheimer’s.
Axovant was formed eight months prior to the IPO and raised roughly $360 million to develop the drug that was essentially abandoned by GlaxoSmithKline. By the end of the first day on the New York Stock Exchange, Axovant had a market capitalization of about $3 billion. Ramaswamy had purchased the drug from Glaxo for $5 million.
Entrepreneur Vivek Ramaswamy Featured on Forbes Cover
Entrepreneur Vivek Ramaswamy Featured on Forbes Cover

A graduate of Harvard College with an A.B. in biology and the recipient of a law degree from Yale Law School, Ramaswamy is a former hedge fund partner. There were skeptics who wondered how a company could be worth so much. The stock had dipped 12 percent below the IPO price by the beginning of the month.

And while Ramaswamy was touting that Axovant’s goal “is to be the leading biopharmaceutical company focused on the treatment of dementia,” they had yet to generate any revenue, even as other companies were creating drugs to compete with his company’s product.
But now, as Axovant drifts to the backdrop, Ramaswamy is up to his old tricks: rescuing the pharmaceutical industry’s forgotten drugs, according to Forbes. Ramaswamy said Axovant is the first step in a broader mission to liberate abandoned or deprioritized drugs, the report said.
It’s not unprecedented. Drugs like Lipitor and Imbruvica have also almost faced extinction before being presented anew to the world. Ramaswamy hopes to do the same for dozens of companies.
“This will be the highest return on investment endeavor ever taken up in the pharmaceutical industry,” he boasted in the Forbes report. “It will be a pipeline every bit as deep and diverse as the most promising pharma company in the world but with a capital efficiency that is unprecedented.”
As an analyst, Ramaswamy noticed there were several forgotten drugs that he would have liked to invest in but couldn’t. They were trapped in big pharmaceutical firms that had shelved them for strategic or bureaucratic reasons, or in small biotechnology firms that had to focus all their resources on a single product, no matter how good option No. 2 was, the Forbes report said.
The Indian American accomplished successful returns with his company Roivant Sciences’ 76 percent stake in Axovant, as well as turning an $8 million purchase of drugs to treat liver virus hepatitis B into $110 million in Arbutus BioPharma. With Roivant, in May, he bought a psychosis drug for $4 million from Arena Pharmaceuticals and later partnered with a Duke University group known for inventing rare-disease drugs.
Axovant speculators will have to wait until 2017 before they hear any new drug data for Alzheimer’s, during which the stock could drift without a bona fide catalyst, said Forbes. Under the best possible scenario, real benefit to Alzheimer’s patients is years away.
But it would be a mistake to get stuck in the weeds of Roivant’s Alzheimer’s efforts. Ramaswamy’s approach is long term and broad in scope and even if Axovant’s efforts fail, the money raised will help with finding other compounds of drugs that could be more effective.
-+=